Bayer AG’s Unit Submits VEGF Trap-Eye (Aflibercept) For Treatment Of Macular Edema Following Central Retinal Vein Occlusion in Japan

Monday, 7 Jan 2013 06:07am EST 

Bayer AG’s Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) to the Ministry of Health, Labour and Welfare (MHLW) in Japan. The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies. 

Company Quote

2.4 +1.82%
25 Aug 2014